Ant Group Digital Technologies Presents Products and Solutions for International Markets to Facilitate Digital Transformation and Collaboration
15.11.2023 13:18:00 EET | Business Wire | Press release
Ant Group Digital Technologies today presented its products and solutions for international markets at the TrustBridge Forum in Singapore. The company also announced that its revenue from its international business operation has increased by 300% in the past year, with key markets including Malaysia, Indonesia, the Philippines and other emerging economies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231115789131/en/
(Photo: Business Wire)
So far in these markets, Ant Group Digital Technologies has provided customers with advanced technology products and solutions, including:
- mPaaS (mobile Platform-as-a-Service), a cloud-to-end one-stop solution for mobile development,
- ZOLOZ eKYC (electronic Know-Your-Customers)，an AI-powered digital identity verification solution,
- AntChain TaaS (Traceability-as-a-Service)，a Blockchain-based traceability solution combined with the Internet of Things (IoT) technologies,
- ZAN, a full suite of blockchain application development products and services for both institutional and individual Web3 developers, and more.
These products and solutions have been adopted by customers from a variety of industries, such as banking services, telecommunication, real estate, medicine and energy.
In 2022, Kenanga Investment Bank, the largest independent investment bank in Malaysia, utilized Ant Group Digital Technologies' mPaaS to develop Malaysia’s first wealth-centric 'Super App,' providing customers with the best of Kenanga and its partners’ products and services in a simple and easy way.
Earlier this year, Ant Group Digital Technologies leveraged its blockchain expertise and launched the brand ZAN to better serve the Web3 community. ZAN provides a suite of plug-and-play tools and services for Web3 endeavors. Its first batch of partners include HashKey Group, Morpheus Labs and Everest Ventures Group.
During the forum, Geoff Jiang, Senior Vice President of Ant Group and CEO of Ant Group Digital Technologies, shared his insights on the future of technology and innovation.
"Innovative technologies including blockchain, privacy computing, Internet of Things and artificial intelligence are accelerating the digitalization of assets, making transactions more efficient and trustworthy, while bringing greater value for all parties," he said. "At Ant Group Digital Technologies, we are committed to leveraging these innovative technologies to facilitate digital transformation and collaboration, in order to drive innovation, efficiency and trust together with our partners."
Ant Group Digital Technologies has won recognition from industry experts and organizations for providing excellent services to its customers over the past several years. AntChain was recognized by Forbes on the Blockchain 50 list for five consecutive years (from 2019 to 2023). Most recently, in September 2023, ZOLOZ was named as a Representative Vendor for the second consecutive time in the latest Gartner Market Guide for Identity Verification.
About Ant Group Digital Technologies
Ant Group Digital Technologies continues to promote the development and application of digital technologies, introducing leading products like AntChain, Zoloz, SOFAStack, and mPaaS based on its expertise in blockchain, privacy computing, security technology, and distributed database. Ant Group Digital Technologies is committed to working with partners across different industries to support small and medium-sized financial institutions in their digital transformation, enable SMEs in the service industry to operate digitally and facilitate digital collaboration across industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231115789131/en/
Contact information
Media Inquiries
Vick Li Wei
Ant Group
vick.lw@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom